NCT00093795已完成3 期
A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC→P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC→PG)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 4,894
- 试验地点
- 12
- 主要终点
- Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells.
PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
详细描述
OBJECTIVES:
Primary
- Compare disease-free survival in women with node-positive breast cancer treated with 3 different adjuvant chemotherapy regimens comprising dose-dense doxorubicin, cyclophosphamide, paclitaxel, and gemcitabine vs docetaxel, doxorubicin, and cyclophosphamide vs dose-dense doxorubicin, cyclophosphamide, and paclitaxel.
Secondary
- Compare overall survival, recurrence-free interval, and distant recurrence-free interval, in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The patient must consent to participate in the study and must have signed an approved consent form conforming with federal and institutional guidelines.
- •The patient must have a life expectancy of at least 10 years and a Zubrod performance status of 0 or
- •(Comorbid conditions but not the diagnosis of breast cancer should be taken into consideration when determining life expectancy.)
- •The interval between the last surgery for breast cancer staging or treatment and randomization must be no more than 84 days.
- •The tumor must be invasive carcinoma of the breast on histologic examination.
- •All of the following staging criteria must be met:
- •By clinical and pathologic evaluation, primary tumor must be T1-3;
- •By clinical evaluation, ipsilateral nodes must be cN0, cN1, or cN2a;
- •By pathologic evaluation, ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes).
- •Patients must have an estrogen receptor (ER) analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then progesterone receptor (PgR) analysis must be performed. If ER analysis is positive, PgR analysis is desired, but not mandatory. ("Marginal" or "borderline" results [i.e., those not definitely negative] will be considered positive regardless of the methodology used.)
- •Patients must have had either a lumpectomy or a total mastectomy. Patients must have completed one of the following procedures for evaluation of pathologic nodal status.
- •Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes (This approach is strongly recommended.)
- •Sentinel lymphadenectomy alone if one of the following criteria is met:
- •Pathologic nodal staging based on sentinel lymphadenectomy is pN1mi or pN1b
- •Surgeon elects not to remove additional non-sentinel nodes (This approach is strongly discouraged, but will not preclude participation in B-38.)
- •Axillary lymphadenectomy without sentinel node isolation procedure.
- •Patients must have no clinical or radiologic evidence of metastatic disease.
- •Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if bone scans fail to demonstrate metastatic disease. Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy.
- •Patients with aspartate transaminase (AST) or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging fails to demonstrate metastatic disease and the following requirements are met at the time of randomization.
- •Postoperative absolute granulocyte count (AGC) must be greater than or equal to 1200/mm
- •Postoperative platelet count must be greater than or equal to 100,000/mm
- •The following criteria for postoperative evidence of adequate hepatic function must be met:
- •total bilirubin must be less than or equal to ULN for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome due to slow conjugation of bilirubin; and
- •alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and
- •the AST must be less than or equal to 1.5 x ULN for the lab; and
- •alkaline phosphatase and AST cannot both be greater than ULN.
- •Postoperative serum creatinine must be less than or equal to ULN.
- •At the time of randomization, the patient must have had the following: history and physical exam, EKG, and imaging of the chest within the past 3 months and bilateral mammogram within the past 6 months.
- •Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF), measured by Multiple Gated Acquisition (MUGA) scan or echocardiogram, greater than or equal to lower limit of normal (LLN) for the facility performing the procedure and no evidence of regional wall abnormalities.
- •Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
- •Special conditions for eligibility of lumpectomy patients: radiation therapy and surgery. Patients treated by lumpectomy must meet all the eligibility criteria in addition to the following:
- •Generally, lumpectomy should be reserved for tumors less than 5 cm. However, at the investigator's discretion, patients treated with lumpectomy for tumors greater than or equal to 5 cm are eligible if eligibility criteria for lumpectomy are met.
- •The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. In patients for whom pathologic examination demonstrates tumor present at the line of resection, additional operative procedures may be performed to obtain clear margins. This is permissible even if axillary evaluation has been completed. Patients in whom tumor is still present at the resected margin after re-excision(s) must undergo total mastectomy to be eligible. (Patients with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection.)
- •Irradiation of regional lymph nodes is optional, but plans for radiation therapy must be declared by the investigator prior to randomization for stratification purposes.
- •Special conditions for eligibility of mastectomy patients: radiation therapy o Postmastectomy chest wall and/or regional nodal irradiation is optional. Plans for radiation in mastectomy patients must be declared by the investigator prior to randomization for stratification purposes.
- •Ineligibility Criteria
- •Male patients are not eligible for this study. Women with one or more of the following conditions or prior therapies are also ineligible for this study:
- •Tumor that has been determined to be human epidermal growth factor receptor 2 (HER2)-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification).
- •Contralateral breast cancer (invasive or DCIS) or a mass or mammographic abnormality in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant.
- •Primary tumor staged as T4 for any reason.
- •Clinical nodal stages including cN2b and cN3 or pathologic nodal stages including pN0(i+), pN2b, pN3b with clinically apparent internal mammary nodes, or pN3c.
- •Suspicious nodes in the contralateral axilla or suspicious supraclavicular nodes. Patients with these conditions are considered ineligible unless there is biopsy evidence that these are not involved with tumor.
- •Prior history of breast cancer, including DCIS (patients with a history of LCIS are eligible).
- •Treatment, including radiation therapy, chemotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. One exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before study entry. In such a case, hormonal therapy must stop at or before randomization and be re-started, if indicated, following chemotherapy. A second exception is radiation therapy for patients enrolled in NSABP B-39 and assigned to partial breast irradiation (Group 2). These patients may have received RT prior to B-38 study entry.
- •Prior therapy with anthracyclines or taxanes for any malignancy.
- •Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible if this therapy is discontinued prior to randomization.)
- •Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other selective estrogen-receptor modulators (SERMs), either for osteoporosis or breast cancer prevention. (Patients are eligible only if these medications are discontinued prior to randomization.
- •Cardiac disease that would preclude the use of anthracyclines. This includes:
- •history of myocardial infarction documented by elevated cardiac enzymes or regional wall abnormalities on assessment of left ventricular (LV) function;
- •angina pectoris that requires the use of anti-anginal medication;
- 另有 18 项未显示
排除标准
- 未提供
研究组 & 干预措施
Group 3: AC X 4 then PG X 4
Experimental
Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
干预措施: Gemcitabine (Drug)
Group 3: AC X 4 then PG X 4
Experimental
Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
干预措施: Cyclophosphamide (Drug)
Group 1: TAC X 6
Active Comparator
Doxorubicin, cyclophosphamide, and docetaxel.
干预措施: Cyclophosphamide (Drug)
Group 1: TAC X 6
Active Comparator
Doxorubicin, cyclophosphamide, and docetaxel.
干预措施: Docetaxel (Drug)
Group 1: TAC X 6
Active Comparator
Doxorubicin, cyclophosphamide, and docetaxel.
干预措施: Doxorubicin (Drug)
Group 2: AC X 4 then P X 4
Active Comparator
Doxorubicin, cyclophosphamide, and paclitaxel
干预措施: Cyclophosphamide (Drug)
Group 2: AC X 4 then P X 4
Active Comparator
Doxorubicin, cyclophosphamide, and paclitaxel
干预措施: Paclitaxel (Drug)
Group 2: AC X 4 then P X 4
Active Comparator
Doxorubicin, cyclophosphamide, and paclitaxel
干预措施: Doxorubicin (Drug)
Group 3: AC X 4 then PG X 4
Experimental
Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
干预措施: Paclitaxel (Drug)
Group 3: AC X 4 then PG X 4
Experimental
Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
干预措施: Doxorubicin (Drug)
结局指标
主要结局
Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer
时间窗: 5 years
The percentage of patients alive and cancer-free.
次要结局
- Overall Survival(5 years)
- Recurrence-free Interval: Time to First Local, Regional, or Distant Recurrence(5 years)
- Distant Recurrence-free Interval: the Time to Distant Disease Recurrence Only(5 years)
- Toxicity(30 days after the last dose of study therapy (about 7 months after study entry))
研究者
研究点 (12)
Loading locations...
相似试验
已完成
3 期
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)Head and Neck CancerNCT00095875Dana-Farber Cancer Institute145
已完成
3 期
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer PatientsBreast CancerNCT01099436Borstkanker Onderzoek Groep250
已完成
3 期
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast CancerBreast CancerNCT00087178NSABP Foundation Inc2,722
进行中（未招募）
3 期
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerBreast CancerNCT00070564SWOG Cancer Research Network3,294
已完成
3 期
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate CancerProstate CancerNCT00255606Tampere University360